Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines

Chemotherapy

Volumn 54, Issue 5, 2008, Pages 343-351

  Namwat, Nisana ^a,b   Amimanan, Piyawan ^a,b   Loilome, Watcharin ^a,b   Jearanaikoon, Patcharee ^b   Sripa, Banchob ^a,b   Bhudhisawasdi, Vajarabhongsa ^a,b   Tassaneeyakul, Wichittra ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

5 Fluorouracil; Cholangiocarcinoma; Drug resistance; Transcriptional profile

Indexed keywords

APOPTOSIS INHIBITOR; BIRC5 PROTEIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URACIL DNA GLYCOSIDASE;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DELTA NP73; FASCIOLIASIS; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TP73 GENE;

CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, MESSENGER;

EID: 49549103540     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151541     Document Type: Article

References (41)

1. Sripa B, Pairojkul C: Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008;24:349-356.
2. Blechacz BR, Gores GJ: Cholangiocarcinoma. Clin Liver Dis 2008;12:131-150, ix.
3. Olnes MJ, Erlich R: A review and update on cholangiocarcinoma. Oncology 2004;66:167-179.
4. Todoroki T: Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000;47:644-649.
5. Longley DB, Harkin DP, Johnston PG:5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338.
6. Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, Adoniou E, Gryniatsos J, Felekouras E, Zacharakis M, Sigala F, Bacoyiannis C, Papastratis G, Papalambros E: Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. Chemotherapy 2007;53:282-291.
7. Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005;16 (suppl 2):ii93-ii96.
8. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
9. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
10. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-2376.
11. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999;5:883-889.
12. Zhou ZW, Wang GQ, Wan S de, Lu ZH, Chen YB, Li S, Chen G, Pan ZZ: The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007;53:127-131.
13. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H, Nakao M, Miki T: Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer 2003;39:541-547.
14. Mizutani Y, Wada H, Fukushima M, Yoshida O, Ukimura O, Kawauchi A, Miki T: The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. Eur J Cancer 2001;37:569-575.
15. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
16. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
17. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ, Vokes EE: Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-313.
18. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000;6:1378-1384.
19. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-1670.
20. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 2005;49:345-351.
21. Habara K, Ajiki T, Kamigaki T, Nakamura T, Kuroda Y: High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro. Jpn J Cancer Res 2001;92:1127-1132.
22. Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Hausler P, Becker H, Liersch T: Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-568.
23. Salva Lacombe P, Garcia Vicente JA, Costa Pages J, Lucio Morselli P: Causes and problems of nonresponse or poor response to drugs. Drugs 1996;51:552-570.
24. Takechi T, Koizumi K, Tsujimoto H, Fukushima M: Screening of differentially expressed genes in 5-fluorouracil-resistant human gastrointestinal tumor cells. Jpn J Cancer Res 2001;92:696-703.
25. De Angelis PM, Kravik KL, Tunheim SH, Haug T, Reichelt WH: Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 2004;3:11.
26. Jin J, Huang M, Wei HL, Liu GT: Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol 2002;8:1029-1034.
27. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M: Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res 2007;27:2241-2249.
28. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, Park IS, Chun JH, Kim IH, Kim IJ, Kang HC, Park JH, Bae JM, Lee JS, Park JG: DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 2004;316:781-789.
29. De Angelis PM, Fjell B, Kravik KL, Haug T, Tunheim SH, Reichelt W, Beigi M, Clausen OP, Galteland E, Stokke T: Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol 2004;24:1279-1288.
30. Naus PJ, Henson R, Bleeker G, Wehbe H, Meng F, Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol 2007;46:222-229.
31. Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol 2005;11:2748-2753.
32. Ikeguchi M, Hirooka Y, Makino M, Kaibara N: Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. Oncol Rep 2001;8:621-625.
33. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH: TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005;12:1564-1577.
34. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
35. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T: Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;38:167-176.
36. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000;159:95-101.
37. Obama K, Kanai M, Kawai Y, Fukushima M, Takabayashi A: Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells. Int J Oncol 2002;21:309-314.
38. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E: Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 2004;64:8167-8176.
39. Okumura K, Shiomi H, Mekata E, Kaizuka M, Endo Y, Kurumi Y, Tani T: Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 2006;15:875-882.
40. Dusseau C, Murray GI, Keenan RA, O'Kelly T, Krokan HE, McLeod HL: Analysis of uracil DNA glycosylase in human colorectal cancer. Int J Oncol 2001;18:393-399.
41. Wang Z, Fukuda S, Pelus LM: Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004;23:8146-8153.